Mithra Pharmaceuticals SA
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Mithra Pharmaceuticals SA
Private Company Edition: Westlake Village BioPartners’ latest launch 3T Biosciences also licensed a second TCR platform from Stanford University. In other recent financings, Senda raised a $123m series C round, Orna revealed a $221m series B and CPRIT funded several cancer drug developers.
Following a trio of complete response letters received since late 2018, Mayne Pharma and partner Mithra Pharmaceuticals have finally obtained US FDA approval for a generic version of Organon’s NuvaRing vaginal hormonal contraceptive ring.
Close to 90% of the FDA’s 2021 first half novel approvals were cleared in the US before Europe, while the EU’s EMA acted first on only 15% of its first half marketing authorizations for new active substances. Exclusive Pink Sheet analysis explores use of expedited review schemes, special pathways and other comparative trends.
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to include five new products, including Roche’s Enspryng for neuromyelitis optica spectrum disorder.
- Other Names / Subsidiaries
- Estetra SA
- Estetra SPRL
- Mithra IBD SA
- Mithra RDP SA
- Mithra Pharmaceuticals CDMO